Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy

Abstract

Our results demonstrate several differences between SC and orthotopic models at basal state, which tend to become similar after therapy. These results emphasize the need to take into account tumor implantation sites when performing preclinical studies with immunotherapeutic agents.